NCT06887803View on ClinicalTrials.gov

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

July 31, 2028

Conditions
Myelofibrosis (MF)
Interventions
DRUG

Roginolisib

IOA-244: 80 mg (corresponding to 72 mg roginolisib) Ruxolitinib: up to 25 mg BD

Trial Locations (3)

20089

RECRUITING

IRCCS Clinical Institute Humanitas, Rozzano

50134

RECRUITING

Azienda Ospedaliero Universitaria Careggi Firenze, Struttura Complessa di Ematologia, Florence

08908

NOT_YET_RECRUITING

Avigunda Gran via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat, Barcelona

Sponsors

Lead Sponsor

iOnctura
All Listed Sponsors
lead

iOnctura

INDUSTRY

NCT06887803 - A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors | Biotech Hunter | Biotech Hunter